Skip to main content

Advertisement

SpringerLink
Log in

Going Third Class: Treatment of Steroid-Dependent Ulcerative Colitis

  • Multicenter Seminars: IBD (MUSE: IBD)
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

References

  1. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut. 1994;35:360–362.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Stange EF, Travis SP, Vermeire S, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis. 2008;2:1–23.

    Article  CAS  PubMed  Google Scholar 

  3. Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006;24:319–330.

    Article  CAS  PubMed  Google Scholar 

  4. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–260.

    Article  CAS  Google Scholar 

  5. Garcia-Planella E, Mañosa M, Van Domselaar M, et al. Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids. Dig Liver Dis. 2012;44:206–210.

    Article  CAS  PubMed  Google Scholar 

  6. Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute Clinical Guidelines Committee. American gastroenterologist association institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153:827–834.

    Article  PubMed  Google Scholar 

  7. Dreesen E, Verstockt B, Bian S, et al. Evidence to support monitoring of vedolizumab trough concentration in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2018;16:1937-e8–1946-e8.

    Article  CAS  Google Scholar 

  8. Yacoub W, Williet N, Pouillon L, et al. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study. Aliment Pharmacol Ther. 2018;47:906–912.

    Article  CAS  PubMed  Google Scholar 

  9. Schulze H, Esters P, Hartmann F, et al. A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients. Scand J Gastroenterol. 2018;21:1–7.

    Google Scholar 

  10. FDA New Release. FDA approves new treatment for moderately to severely active ulcerative colitis. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm609225.htm. Accessed May 30, 2018.

  11. Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–1736.

    Article  CAS  PubMed  Google Scholar 

  12. Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM, Kosinski L, Regueiro MD. Ulcerative colitis care pathway. Gastroenterology. 2015;149:238–245.

    Article  PubMed  Google Scholar 

  13. Devaraj B, Kaiser AM. Surgical management of ulcerative colitis in the era of biologicals. Inflamm Bowel Dis. 2015;21:208–220.

    Article  PubMed  Google Scholar 

  14. Singh S, Al-Darmaki A, Frolkis AD, et al. Postoperative mortality among patients with inflammatory bowel diseases: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2015;149:928–937.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Inflammatory Bowel Disease, Perelman School of Medicine, University of Pennsylvania, Perelman Center for Advanced Medicine, 3400 Civic Center Blvd, Room 753 – South Pavilion, Philadelphia, PA, 19104, USA

    Helen Lee, Yecheskel Schneider & Gary R. Lichtenstein

Authors
  1. Helen Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yecheskel Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gary R. Lichtenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gary R. Lichtenstein.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Helen Lee, Yecheskel Schneider: co-first authorship.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, H., Schneider, Y. & Lichtenstein, G.R. Going Third Class: Treatment of Steroid-Dependent Ulcerative Colitis. Dig Dis Sci 64, 1138–1141 (2019). https://doi.org/10.1007/s10620-019-05610-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-019-05610-w

Search

Navigation